
zzso of the zzso and sympathetic nervous systems may alter the cardiac energy zzso zzso thereby contributing to the progression of heart failure with normal ejection zzso We assessed the qualitative and quantitative effects of zzso II zzso zzso and the zzso zzso zzso zzso on cardiac energy metabolism in experimental models of zzso and zzso dysfunction and the role of the zzso II type 1 zzso 

zzso II zzso zzso or zzso (40 zzso was administered to zzso male zzso zzso mice for 14 days via implanted zzso zzso zzso showed concentric zzso and zzso dysfunction, with preserved zzso function in zzso zzso and zzso zzso zzso II induced marked reduction in cardiac zzso zzso and zzso zzso with no change in zzso and fatty acid zzso zzso acid zzso zzso A production and zzso production were reduced in response to zzso zzso zzso zzso zzso zzso 4 expression was zzso by zzso II and zzso resulting in a reduction in the zzso zzso activity, the zzso step for zzso zzso zzso zzso zzso 4 zzso correlated with the zzso of the zzso zzso zzso zzso in response to zzso zzso zzso II type 1 zzso blockade zzso the zzso of the zzso zzso zzso zzso and prevented the reduction in zzso zzso but increased fatty acid zzso 

zzso zzso and zzso zzso and zzso dysfunction is associated with reduced zzso zzso because of the zzso zzso zzso zzso of zzso zzso zzso 4, and targeting these pathways may provide novel therapy for heart failure with normal ejection zzso 

